CLINICAL_TRIALS ClinicalTrials.gov record update

A Preoperative Phase 1B Study to Assess the Safety and the Immunological Effect of Pembrolizumab (Keytruda®) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02930902
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:19.475648+00:00
Published At: 2023-02-09T00:00:00+00:00
Record Updated At: 2023-02-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Resectable Pancreatic Carcinoma", "Stage I Pancreatic Cancer AJCC v6 and v7", "Stage IA Pancreatic Cancer AJCC v6 and v7", "Stage IB Pancreatic Cancer AJCC v6 and v7", "Stage II Pancreatic Cancer AJCC v6 and v7", "Stage IIA Pancreatic Cancer AJCC v6 and v7", "Stage IIB Pancreatic Cancer AJCC v6 and v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-02-09"
protocolSection.identificationModule.nctId: "NCT02930902"
protocolSection.identificationModule.officialTitle: "A Preoperative Phase 1B Study to Assess the Safety and the Immunological Effect of Pembrolizumab (Keytruda\u00ae) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.